PDCD1 and non-small cell lung carcinoma: Furthermore, nivolumab, a humanized monoclonal antibody (mAb) targeting PD-1, is approved by the United States Food and Drug Administration for treating melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin’s lymphoma, head and neck cancer, urothelial carcinoma, and hepatocellular carcinoma [15].